Overview
- The DECAF randomized trial assigned 200 habitual or recent coffee drinkers to drink at least one caffeinated cup daily or avoid caffeine for six months after cardioversion.
- Coffee drinkers had a 39% lower risk of recurrent atrial fibrillation or atrial flutter, with recurrences detected through clinic ECGs and wearable monitoring at scheduled follow-ups.
- Participants were enrolled across hospitals in the United States, Canada, and Australia, and outcomes were assessed at one, three, and six months.
- Researchers noted limits including modest sample size, imperfect adherence in the avoidance group, and findings that reflect moderate intake rather than heavy consumption.
- Experts said the results align with 2023 ACC/AHA guidance that caffeine abstention does not prevent AFib and urged individualized advice for patients considering caffeine use.